Search clinical trials for: Subjects with impaired hepatic function and healthy subjects

Total 476872 results

Atea Pharmaceuticals, Inc.

Recruiting

Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment | Healthy Volunteer

United States
Tetraphase Pharmaceuticals, Inc.

Completed

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

Impaired Hepatic Function

United States
Shire

Completed

Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function

Healthy | Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Hepatic Impairment

Germany, Belgium, Lithuania, United States, Bulgaria, Romania
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function

Healthy Subjects | Hepatic Impairment

China
Novartis Pharmaceuticals

Completed

A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

Hepatic Impairment

United States
Novartis Pharmaceuticals

Terminated

Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment

Hepatic Impairment

United States
Array Biopharma, now a wholly owned subsidiary...

Terminated

MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function (MEK162)

Hepatic Impairment

United States
BeiGene

Completed

Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function

Hepatic Insufficiency & Healthy Subjects

United States
ObsEva SA

Completed

Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment | Healthy Participants

United States
Akebia Therapeutics

Completed

A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

United States
Dong-A Pharmaceutical Co., Ltd.

Completed

A Pharmacokinetic Study of Udenafil in Adult Subjects With or Without Impaired Hepatic Function (udenafil)

Hepatic Impairment

Korea, Republic of
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

Healthy

United States
AstraZeneca

Completed

A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function

Healthy Volunteers | Pharmacokinetics | Hepatic Impairment | Amount of R406 in Blood

United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC278-TiDP6-C130: Pharmacokinetics, Safety and Tolerability of TMC278 in Subjects With Mildly or Moderately Impaired Hepatic Function.

HIV | Hepatic Impairment | AIDS
Novartis

Completed

Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function

Hepatic Insufficiency

United States
Fujian Shengdi Pharmaceutical Co., Ltd.

Recruiting

A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy Subjects

Type 2 Diabetes

China
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function

Chronic Kidney Disease
Atea Pharmaceuticals, Inc.

Recruiting

Study of AT-527 in Subjects With Normal and Impaired Renal Function

Renal Impairment | Healthy Volunteer

Canada
Reata, a wholly owned subsidiary of Biogen

Completed

Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function

Healthy | Hepatic Impairment

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function

Renal Impairment

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function

Hepatic Insufficiency | Healthy Subjects

China
VectivBio AG

Completed

A Phase 1, Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

Germany, Slovakia
Daiichi Sankyo, Inc.

Completed

A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

Hepatic Impairment | Moderate Impaired Hepatic Function

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

Mild and Moderate Hepatic Impairment

United States
Bayer

Completed

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

Overactive Bladder | Diabetic Neuropathic Pain | Endometriosis Related Pain | Refractory or Unexplained Chronic Cough

United States
Sunshine Lake Pharma Co., Ltd.

Completed

To Evaluate the Pharmacokinetics and Safety of Yimitasvir Phosphate Capsules in Subjects With Moderate and Severe Liver Function Impairment and in Healthy Subjects

Hepatic Impairment

China
Chimerix

Completed

Safety and Pharmacokinetics of CMX001 in Impaired Hepatic Function and Healthy Subjects

Hepatic Impairment

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

Renal Impairment

Germany, Bulgaria
Shire

Completed

Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function

Impaired Renal Function

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function

Alcoholism | Hepatic Cirrhosis

Germany, Belgium, United States, South Africa
Novartis Pharmaceuticals

Completed

A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function

Renal Impairment

Germany, Bulgaria
Novartis Pharmaceuticals

Completed

Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects

Non-alcoholic Fatty Liver Disease

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment

Renal Impairment

United States
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Moderate Hepatic Impairment | Normal Hepatic Function

United States
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function

Subjects With Impaired Renal Function and Healthy Subjects
ObsEva SA

Completed

Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function

Renal Impairment | Healthy Participants

United States
Pharmaceutical Project Solutions, Inc.
Cognitive Research Corporation

Completed

Pharmacokinetic Study of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function

Analgesic Allergy

United States
Agios Pharmaceuticals, Inc.

Completed

A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

Hepatic Impairment

United States
Novo Nordisk A/S

Completed

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

Healthy | Diabetes Mellitus, Type 2 | Diabetes

Hungary, Czechia
Syndax Pharmaceuticals

Completed

A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function

Renal Impairment | Healthy Volunteer

United States
Zhejiang Medicine Co., Ltd.
Huashan Hospital

Completed

Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function

Liver Dysfunction

China
Allergan

Completed

Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects

Renal Function

United States
Novo Nordisk A/S

Completed

Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Diabetes Mellitus, Type 2 | Diabetes | Hepatic Impaired

Poland, Slovakia
Amicus Therapeutics

Completed

Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function

Fabry Disease

United States
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function

Healthy | Diabetes

Slovakia
Alkermes, Inc.

Completed

Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function

Hepatic Impairment

United States
AbbVie

Completed

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

United States, New Zealand

3

Subscribe